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The restricted bone marrow (BM) localisation of multiple myeloma (MM) cells most likely results from a specific homing influenced by
chemotactic factors, combined with the proper signals for growth and survival provided by the BM microenvironment. In analogy to
the migration and homing of normal lymphocytes, one can hypothesise that the BM homing of MM cells is mediated by a multistep
process, involving the concerted action of adhesion molecules and chemokines. In this study, we report that primary MM cells and
myeloma derived cell lines (Karpas, LP-1 and MM5.1) express the chemokine receptor CCR2. In addition, we found that the
monocyte chemotactic proteins (MCPs) MCP-1, -2 and -3, three chemokines acting as prominent ligands for CCR2, are produced by
stromal cells, cultured from normal and MM BM samples. Conditioned medium (CM) from BM stromal cells, as well as MCP-1, -2 and
-3, act as chemoattractants for human MM cells. Moreover, a blocking antibody against CCR2, as well as a combination of neutralizing
antibodies against MCP-1, -2 and -3, significantly reduced the migration of human MM cells to BM stromal cell CM. The results
obtained in this study indicate the involvement of CCR2 and the MCPs in the BM homing of human MM cells.
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Multiple myeloma (MM) represents a neoplastic B-cell disorder,
characterised by a monoclonal and uncontrolled expansion of
malignant plasma cells within the bone marrow (BM) compartment
(Ludwig et al, 1999). Although MM cells primarily localise in the
BM, they can also be found in the circulation, and the number of
circulating cells increases at very advanced stages of disease. It can
be assumed that these circulating MM cells are involved in disease
spreading and must therefore have the potential to extravasate and
home to the BM (Van Riet et al, 1998). In analogy to the migration
and homing of normal lymphocytes, the BM homing of MM cells is
likely to be mediated by specific mechanisms, involving the action
of locally produced factors with chemotactic properties (Butcher
and Picker, 1996). Chemokines are a family of small, structurally
related cytokines with chemoattractant and activation properties
involved in several types of inflammatory reactions (Oppenheim
et al, 1991). They are characterised by the presence of a conserved
cysteine motif near the N-terminal end. They can be classified into
four distinct groups (C, CC, CXC and CX3C chemokines) based on
the presence or absence of an amino-acid sequence separating the
two first cysteines (Baggiolini et al, 1994; Premack and Shall, 1996).
They are produced by a number of cell types, including leukocytes,
endothelial cells, fibroblasts and stromal cells. Chemokines act on
responsive cell types through G-protein coupled seven transmem-
brane receptors (Murphy et al, 1994). They have primarily been
functionally related to leukocyte trafficking, but recent reports
suggest their role in cancer development and progression as well
(Strieter, 2001; Muller et al, 2001).
CCR2 is a chemokine receptor that is expressed on peripheral
blood monocytes, as well as activated T cells, B cells and immature
dendritic cells (Frade et al, 1997; Vecchi et al, 1999). Gene-targeted
mice lacking CCR2 (CCR2 /  mice) exhibit defects in monocyte/
macrophage trafficking to sites of inflammation (Kurihara et al,
1997; Boring et al, 1998; Peters et al, 2000). The known ligands
for CCR2 include the monocyte chemotactic proteins (MCPs)
MCP-1, -2 and -3 belonging to the family of CC chemokines
(Mellado et al, 1998). They act as potent activators and
chemoattractants for monocytes, basophils, eosinophils, T-lympho-
cyte subsets, dendritic cells and endothelial cells, but not
neutrophils (Baggiolini et al, 1994; Salcedo et al, 2000). In
addition, MCP-1 and -3 have shown antitumour activity by
chemokine gene transfer in mouse models (Hoshino et al, 1995;
Fioretti et al, 1998). MCP-1 has also been implicated in
angiogenesis (Salcedo et al, 2000).
To date, very few data are available about the effects of
chemokines on human MM cell migration (Woodliff and Epstein,
1999, 2000). In this study, we analysed the functional expression of
CCR2 on MM cell lines (HMCL) as well as primary MM cells from
BM of MM patients. Our data demonstrate that HMCL, as well as
primary MM cells, express CCR2. In addition, the MCPs, produced
by BM stromal cells, felicitated migration responses, suggesting a
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ypotential contribution to the homing of MM cells to the BM
microenvironment.
MATERIALS AND METHODS
Chemokines and antibodies
The human recombinant monocyte chemotactic proteins MCP-1,
-2 and -3 were obtained from Biosource. Monoclonal antibodies
(MoAb) against MCP-1, -2 and -3 were purchased from R&D. The
CCR2 MoAb was a kind gift from Dr C Clement (Millennium
Pharmaceuticals, Cambridge, MA, USA).
Cell lines
Three well-characterised human MM cell lines (HMCL) (LP-1,
Karpas and MM5.1) were selected for our experiments. They were
kept in culture as described (Nilson, 1971; Okuno et al, 1991; Van
Riet et al, 1997).
Patient samples
BM samples from 28 MM patients (pts) (age 41–94 years, mean 66)
were collected during standard diagnostic procedures. Each MM
patient was diagnosed and staged according to the criteria of Durie
and Salmon (1975). The study was approved by the local ethical
committee. BM aspirates were obtained from the posterior iliac
crest or sternum and collected in a heparinised syringe. Mono-
nuclear cells (MNC) were separated by Ficoll density gradient
centrifugation (Nycomed, Lucron, Gent, Belgium).
MACS separation of primary MM cells
Primary MM cells were immunomagnetically separated using the
magnetic cell sorting system (MACS) (Miltenyi Biotech Sanver-
tech, Bouchout, Belgium). MNC were incubated for 15min at 41C
with MACS microbeads conjugated to a monoclonal mouse CD138
(syndecan-1) antibody (clone B-B4, isotype mouse IgG1). Cells
were washed once in PBS supplemented with human albumin
(4%), resuspended and separated on a column placed in the
magnetic field of the MACS separator. CD138+ cells were retained
and eluted as a positively selected cell fraction after removal of the
column from the magnetic field. Cells were counted and viability
was assessed with trypan blue. MACS purification produced a 98%
pure primary MM cell population as determined by May –
Gru ¨nwald – Giemsa-stained cytospin preparation.
BM stromal cell culture and conditioned medium
MNC from BM samples obtained from MM patients and normal
controls were cultured in 75cm
2 flasks (Nunc, VWR International,
Leuven, Belgium) in RPMI supplemented with 12.5% foetal calf
serum (FCS) and 12.5% horse serum at 371C with 5% CO2. After
3–5 weeks of culture, a confluent layer was obtained and stromal
cells were detached by trypsinisation. After one passage, estab-
lished confluent cell layers were cultured for 5 days in serum-free
medium (RPMI) and culture supernatant was harvested as
conditioned medium (CM). CM was centrifuged to remove cell
debris and frozen at  201C until use. CM preparations from
different cell cultures were prepared.
RNA extraction, cDNA synthesis and reverse transcription
polymerase chain reaction (RT–PCR)
Total RNA was extracted from cultured HMCL and cultured BM
stromal cells from normal and MM BM samples using the RNeasy
Mini Kit (Qiagen), according to the manufacturer’s instructions.
First-strand cDNA was generated from 5mg of total RNA with the
SUPERSCRIPTt Preamplification System (GIBCO BRL) according
to the instructions made by the manufacturer. The amount of DNA
corresponding to 1/10 of the cDNA obtained by reverse transcrip-
tion was amplified with a PCR protocol in the presence of
HotStarTaq Master Mix (Qiagen) and primer pairs (10mM) (GIBCO
BRL) in a 25ml reaction mixture. The following primers were used
for amplifying mRNA: CCR2 sense: 50-TGG CTG TGT TTG CTT
CTG TC-30 and CCR2 antisense: 50-TCT CAC TGC CCT ATG CCT
CT-30, (actin sense: 50-TGC CTA TCC AGG CTG TGC TAT-30 and
actin antisense: 50-GAT GGA GTT GAA GGT AGT TT-30; MCP-1
sense: 50-CTC AGC CAG ATG CAA TCA ATG C-30 and MCP-1
antisense: 50-CCT CAA GTC TTC GGA GTT TGG G-30; MCP-2
sense: 50-ATG CTG AAG CTC ACA CCC TTG CCC-30 and MCP-2
antisense: 50-CAG ATG CTT CAT GGA ATC CCT GAC C-30; MCP-3
sense: 50-CAG ATT TAT CAA TAA GAA AAT CCC-30 and MCP-3
antisense: 50-GTG CTT CAT AAA GTC CTG GAC CC-30 (Dumoulin
et al, 1999). The PCR profile consisted of an initial activation step
of 15min at 951C, a 1min initial denaturation at 941C, followed by
30 cycles of 1min denaturation at 941C, 1min annealing at 58, 55,
58, 68 and 541C for CCR2, actin, MCP-1, -2 and -3, respectively,
2min renaturation at 721C and finally 10min extension at 721C.
PCR products were analysed by electrophoresis in a 2% agarose
gel, visualised by ethidium bromide and photographed (Kodak
EDAS 290). The amplified mRNA was identified based upon the
anticipated size by comparison with DNA ladder of known
molecular sizes.
Flow cytometry
Flow cytometry was used to assess CCR2 expression on the surface
of HMCL and primary MM cells. For phenotyping the HMCL, cells
were first incubated with mouse anti-human CCR2 MoAb (IgG2a)
or control mouse IgG2a (both at 10mgml
 1) for 30min at 41C. In
the second step, cells were incubated with PE-conjugated goat anti-
mouse IgG2a antiserum (Southern Biotechnology InTec, Antwer-
pen, Belgium) for 30min at 41C. Cells were washed, resuspended in
PBS and analysed on EPICS XL flow cytometer (Coulter Electronics
Analis, Namur, Belgium). CCR2 expression on the surface of
primary MM cells and normal plasma cells was evaluated by a
double-staining procedure. MNC, isolated from BM samples of
MM patients and normal controls by Ficoll gradient centrifugation,
were incubated with CCR2 MoAb as described and a Cy-5-
conjugated CD38 specific antibody (HIT2) (Becton Dickinson
Erembodgem, Belgium). In the second step, cells were incubated
with PE-conjugated goat anti-mouse IgG2a antiserum (Southern
Biotechnology). The fluorescence intensity was calculated from the
fluorescence histogram and expressed as the fluorescence intensity
ratio (FiR) (specific fluorescence/control fluorescence). A FiR
value of more than 1.6 was considered positive.
In vitro cell migration assay
Migration of HMCL and primary MM cells was assayed using
Transwellt cell culture inserts (Costar Corning Elscolab, Krui-
bekes, Belgium) as described previously (Vande Broek et al, 2001).
CM from BM stromal cells or recombinant chemokines MCP-1, -2
and -3, diluted in 300ml RPMI 1640 medium in varying
concentrations, were placed into 24-well culture plates (Costar
Corning). Transwellt inserts (6.5 mm diameter, 8mm pore size)
were placed in each well and 1 10
5 MM cells in 100ml RPMI were
added to the upper chamber. Cells were allowed to migrate for 4h
at 371C with 5% CO2, after which inserts were removed. The
number of cells that transmigrated into lower wells was evaluated
in two ways. For HMCL, a colorimetric assay with WST-8 was used
(Cell Counting Kit-8 (Alexis)). WST-8 was added in each well and
incubated for 4h at 371C. The absorbance of converted stain was
then measured spectrophotometrically with a 96-well microplate
reader (Ceres 900, Bio-Tek International Inc, Brussels, Belgium) at
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primary MM cells, transmigrated cells were recovered from lower
wells and counted with a FACSort flow cytometer (Becton
Dickinson Erembodgem, Belgium). A known number of sphero
blank calibration beads (Becton Dickinson Erembodgem, Belgium)
were used as internal standard. Experiments were performed in
triplicate and the mean with standard deviations (s.d.) was
calculated. Migration responses were determined as the mean
increase in cell migration as compared to control (spontaneous)
migration. For migration-inhibition experiments, cells were
preincubated for 30min with a blocking CCR2 MoAb. In some
experiments, cell migration was assayed in the presence of
neutralising MoAbs against MCP-1, -2 and -3, which had been
added to lower wells.
RESULTS
CCR2 is expressed by human MM cell lines (HMCL) and
primary MM cells from patient BM samples
We first determined the expression of CCR2 by HMCL using RT
– PCR and flow cytometry. RT – PCR of MM cell mRNA with
specific primers for CCR2 showed the presence of CCR2
transcripts in all three HMCL tested (Figure 1A). Flow cytometry
with CCR2 MoAb demonstrated surface expression of CCR2 in all
three HMCL (Figure 1B). Subsequently, we analysed surface
expression of CCR2 on primary MM cells in BM samples from
MM patients and normal controls using a two-colour staining
method. FACS profiles revealed that CCR2 was expressed on
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Figure 1 Expression of CCR2 chemokine receptor (A and B) and in vitro migration to MCP-1, -2 and -3 (C) by HMCL. CCR2 expression on HMCL was
analysed by RT–PCR (A) and flow cytometry (B). RT–PCR analysis from total RNA extracted from HMCL with CCR2-specific primers showed a specific
230bp PCR fragment in all three HMCL tested. Analysis of actin mRNA expression (446bp PCR fragment) served as an internal control. Water was used as
negative control. FACS analysis showed surface expression of CCR2 on HMCL. Results are shown as fluorescence histograms (open histogram: CCR2
expression; filled histogram: isotype-matched control antibody). Three HMCL were tested for their ability to migrate across 8mm pore-size polycarbonate
filters in response to different MCP-chemokine concentrations as indicated (C). Values are expressed as the percentage increase of control migration to
serum-free medium. Results shown are the mean and s.d. of three independent experiments.
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tested (n¼28). Results of CCR2 expression in primary MM cells
from four BM samples are illustrated in Figure 2A. Among the
positive cases, the mean fluorescence intensity varied between 1.6
and 14.4. CCR2 was also found to be expressed on plasma cells
from all normal BM samples tested (n¼10) (data not shown).
MCP-1, -2 and -3 act as chemoattractants for HMCL and
primary MM cells
Since HMCL and primary MM cells express CCR2, the major
chemokine receptor for the MCPs, it can be assumed that MCP-1,
-2 and -3 function as chemoattractants for human MM cells.
Therefore, we evaluated the migration of HMCL and primary MM
cells in the presence of MCP-1, -2 and -3. Addition of MCP-1, -2
and -3 at concentrations from 1 to 1000ngml
 1 to the lower
compartments of the migration system resulted in a concentration-
dependent stimulation of MM cell migration (Figure 1C). In the
three HMCL, the maximal increase in cell migration to MCP-1
ranged between 38 and 75%, corresponding with 21–28% of the
total number of cells in the upper compartment that actively
migrated through the membrane into the lower compartment of
the Transwell migration system. For MCP-2, the maximal increase
in migration observed, varied between 41 and 56%, corresponding
with 25–28% of the total number of input cells that migrated
through the filter. In the presence of MCP-3, the maximal increase
in migration observed, ranged between 54 and 68%, corresponding
with 27–30% of the cells migrating to the lower compartment.
Similar results were obtained using isolated primary MM cells
from three MM patients (Pts 1 – 3), which were positive for CCR2.
For all these patients, the most pronounced migration response
was observed with MCP-1. In the presence of this chemokine, we
observed an increase in cell migration between 48 and 60%,
corresponding with 29–48% of cells migrating to the lower
compartment. In one MM patient with CCR2-negative plasma cells
(Pt 4), no significant migration response towards MCP-1, -2 or -3
could be observed (Figure 2).
BM stromal cells express mRNA for MCP-1, -2 and -3
Using specific primers for MCP-1, -2 and -3, we amplified PCR
products of expected sizes (372, 300 and 160bp, respectively) from
cDNA of stromal cells, cultured from normal and MM BM samples
(Figure 3). Analysis of actin mRNA expression served as an
internal control. These findings indicate that BM stromal cells
from MM BM samples and normal controls produce the
chemokines MCP-1, -2 and -3.
Conditioned medium (CM) from BM stromal cells
stimulates MM cell migration
We next determined whether supernatants from cultured BM
stromal cells could stimulate MM cell migration. Migration of
HMCL and primary MM cells was determined as described in
Materials and Methods. CM was placed in the lower compartments
of the migration system. As shown in Figure 4A, the migration
response of HMCL and primary MM cells was significantly
enhanced (67 – 83 and 52 – 89% respectively, corresponding with
25 – 28 and 38 – 41% of migrating cells, respectively) when
compared to control migration to serum-free RPMI medium. No
differences were found in migration responses to CM from stromal
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Figure 2 Expression and functionality of CCR2 on primary MM cells from BM samples: (A) FACS analysis of CCR2 on primary MM cells: Results are
shown as fluorescence histograms. The open histogram shows CCR2 expression; the filled histogram represents the isotype-matched control antibody.
Representative results of CCR2 expression from four different BM samples are shown. (B) In vitro cell migration to MCP-1, -2 and -3 was assayed using
immunomagnetically isolated primary MM cells from four patient BM samples. Chemokines were used at 100ngml
 1. The number of migrated cells was
quantified by flow cytometry. Data represent the percentage increase of control migration. Representative values are shown for experiments with primary
MM cells from four patient samples.
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Figure 3 Expression of MCP-1, -2 and -3 in human BM stroma from MM patients and normal controls. Total RNA was isolated from cultured human BM
stromal cells from MM patients and normal controls, and subjected to reverse transcription and PCR amplification for MCP-1, -2 and -3 using appropriate
primers. The specific 372, 300 and 160bp PCR fragments for MCP-1, -2 and -3, respectively, were detected in all normal and MM BM samples tested.
Analysis of actin mRNA expression (446 bp PCR fragment) served as an internal control. Water was used as negative control.
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Figure 4 Effect of CM from BM stromal cells on human MM cell migration and inhibition by anti-CCR2 MoAb. In vitro cell migration was analysed by in
vitro Transwell migration assay. BM CM was added to the lower compartment. Migration of three HMCL (Karpas, MM5.1 and LP-1) and primary MM cells
from four MM patient samples was assayed. Results are expressed as the percentage increase of control migration to serum-free medium (A). For migration-
inhibition experiments, MM cells were preincubated with a MoAb against the chemokine receptor CCR2 or a control antibody (IgG2a) prior to the
migration assay. Results indicate the relative migration compared with control migration to CM and represent the mean value7s.d. of three experiments
with Karpas cells. Representative values are also shown for experiments with primary MM cells from three MM patients (B).
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MM BM samples (data not shown).
CM-induced MM cell migration is inhibited by MoAbs
against CCR2 and MCP-1, -2 and -3
To determine whether the chemokines MCP-1, -2 and -3 produced
by BM stromal cells are involved in the chemoattractive effect of
BM CM, we performed migration experiments with MM cells
towards BM CM in the presence of a blocking CCR2 MoAb or
neutralising MCP MoAbs. MM cells were preincubated with CCR2
MoAb prior to the migration assay, and migration responses
towards BM CM were analysed. In some experiments, MCP-1, -2
and -3 MoAbs were added to the lower compartment of the
migration system together with CM. MM cell migration to BM was
significantly inhibited by CCR2 MoAb up to 40% for Karpas cells
and up to 52% for the patient samples (Figure 4B). The presence of
one single MoAb against MCP-1, -2 or -3 did not significantly
affect MM cell migration to BM CM, but in the presence of three
MoAbs together against MCP-1, -2 and -3, MM cell migration was
reduced up to 40% for Karpas cells and up to 50% for the isolated
primary MM cells (Figure 5A,B). These experiments clearly
demonstrate that CM-induced MM cell migration involves
MCP-1, -2 and -3 and that MM cell migration to MCPs occurs
through CCR2.
DISCUSSION
A striking feature of MM represents the selective localisation of
malignant plasma cells in the BM. The mechanisms by which MM
cells traffic to and accumulate in the BM are not fully understood.
In analogy to the migration and homing of normal lymphocytes
(Butcher and Picker, 1996), one can hypothesise that the BM
homing of MM cells is mediated by a multistep process. First,
circulating cells reversibly roll onto the endothelium, followed by a
firm adhesion, transendothelial migration with passing through
the basement membrane and finally migration to the extracellular
matrix. Our group has demonstrated that murine 5T2 MM cells
selectively migrate to the BM, the spleen and the liver, but only
survive within the BM compartment and the spleen. So, the
selective localisation of MM cells in the BM likely results from a
combination of a selective homing and survival in the BM
(Vanderkerken et al, 2000). In the same murine 5T model, we
could also recently demonstrate that the BM homing of MM
involves the adhesion receptor CD44v6 that mediates binding to
BM endothelium (Asosingh et al, 2000). It is believed that homing
not only requires specific cellular adhesion, but also depends on
the interaction of locally produced chemoattractants with specific
cell surface receptors (Butcher and Picker, 1996). Previously, we
have demonstrated that laminin-1, a major component of the
basement membrane, acts as a potent chemoattractant for human
MM cells, indicating a key role for extravasation through the
basement membrane (Vande Broek et al, 2001). In addition, MM
cells were found to express the high-affinity laminin binding
protein 67LR, which appeared to be upregulated by contact with
the endothelium, indicating that during passage through the
basement membrane, 67LR is contemporary upregulated allowing
MM cells to be sensible to the chemoattractive properties of
laminin-1, and so facilitating transendothelial migration. As a
result of the broad expression of laminin-1 in basement
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Figure 5 In vitro MM cell migration to CM is inhibited by anti-MCP MoAb. MoAb against MCP-1, -2 and -3 or control antibody (IgG1) was added together
with CM to the lower compartment of the migration system. Results indicate the relative migration compared with control migration to CM and represent
the mean value7s.d. of three experiments with Karpas cells (A). Representative values are shown for experiments with primary MM cells from three MM
patients (B).
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itself cannot be the only factor that determines the specificity of
MM cell homing to the BM. We therefore focussed on other
molecules with chemoattractive potential and started to analyse the
particular role of chemokines in the BM homing process of MM
cells. Chemokines represent a family of growing interest and recent
findings indicate that these molecules are implicated in a complex
network of signalisation between tumour cells and the micro-
environment of the host (Amann et al, 1998; Ferrero et al, 1998).
We report here that HMCL and primary MM cells freshly
isolated from the BM of MM patients express the chemokine
receptor CCR2, as analysed by RT–PCR and/or flow cytometry.
The chemokine receptor CCR2, together with CCR5, plays an
important role in the recruitment of monocytes/macrophages and
T cells in various inflammatory diseases, infection and arterio-
sclerosis (Kurihara et al, 1997; Boring et al, 1998). Previous reports
have demonstrated that CCR2 is expressed on normal, mature B
cells (Frade et al, 1997). Very recently, transcripts for this receptor
were also identified in myeloma plasma cells, as demonstrated by
cDNA arrays (De Vos et al, 2001). Our data show that CCR2 is also
expressed in both, normal and malignant plasma cells, at the
protein level. To our knowledge, no reports have been published
yet describing the expression of the chemokine receptor CCR2 in
other B-cell malignancies. Using Transwellt migration assays, we
could demonstrate that CCR2 expression on MM cells was
functional since ligands of CCR2, that is MCP-1 as well as
MCP-2 and -3, act as chemoattractants for human MM cells.
Compared to control migration in the absence of chemoattractant,
we noticed an increased cell migration response up to 80% for
MCP-1, 60% for MCP-2 and 70% for MCP-3.
To investigate whether CCR2 and MCP-1, -2 and -3 are directly
involved in the BM homing of MM cells, we first analysed the
production of MCP-1, -2 and -3 by human stromal cells, cultured
from normal and MM BM samples. A previous report described
the production of MCP-1 by murine BM stromal cells (Xu et al,
1999). Moreover, MCP-2 mRNA has been identified in human BM
stromal cells (Van Coillie et al, 1997). In this study, we
demonstrated by RT–PCR, that BM stromal cells in MM samples
express transcripts for MCP-1, -2 and -3. To determine the role of
these chemokines in mediating MM cell migration to CM from
cultured BM stromal cells, we performed in vitro migration assays
in the presence of a blocking CCR2 MoAb. A reduction in cell
migration up to 52% was observed. Additionally, in vitro
migration assays were performed in the presence of neutralising
MoAbs against MCP-1, -2 and -3. Interestingly, we observed no
reduction of cell migration in the presence of one single MoAb or a
combination of two MoAbs, but a clear reduction in MM cell
migration was found when the three chemokines were neutralised
simultaneously. It seems that preventing the binding of two MCP
molecules to CCR2 still allows the third MCP to elucidate
migration responses. Inhibition of the migration response to CM
from BM stromal cells with a blocking CCR2 MoAb and
neutralising MCP MoAbs indicates that MCP-1, -2 and -3 represent
a major chemotactic activity for MM cells released by BM stroma.
Moreover, the recent finding that IL-6, a major growth factor in
MM, can upregulate the production of MCP-1 (Biswas et al, 1998)
suggests that at least one of these chemokines is abundantly
present in the BM microenvironment of MM patients. The fact that
blocking of CCR2 binding to MCP-1, -2 and -3 does not induce
complete inhibition of MM cell migration suggests that one or
more additional chemoattractant(s) is (are) involved in the BM
homing of MM cells. Recent data indicate that human MM cells
express the chemokine receptor CXCR4 and that this receptor
mediates in vitro migration of MM cells to SDF-1, a BM stromal-
derived factor (Woodliff and Epstein, 1999). Moreover, it was
found that CXCR4-positive, but not CXCR4-negative, MM cell lines
home to the BM in SCID mice, suggesting the involvement of this
particular receptor in the BM homing of MM cells as well
(Woodliff et al, 2000). Another chemokine that might influence the
migration behaviour of MM cells is MIP-1a. This chemokine was
found to be secreted at elevated levels by BM cells of MM patients
and has been related to osteoclast activation (Choi et al, 2000).
Future experiments have to explore at which level SDF-1 and MIP-
1a co-act with the MCPs to mediate the chemoattraction of MM
cells to the BM.
The fact that CCR2 was also found to be expressed by normal
plasma cells and its ligands were found to be secreted by normal
stromal cells as well indicates that these receptor–ligand interac-
tions might be involved in normal plasma cell homing as well. One
study described that CCR2 /  mice do not show obvious
haematological abnormalities, but the distribution and BM homing
of normal plasma cells was not evaluated (Kurihara et al, 1997).
In conclusion, the results obtained in this study indicate that
MM cells express CCR2 and that this chemokine receptor is
functional. In addition, the monocyte chemotactic proteins MCP-1,
-2 and -3, produced by BM stroma, act as chemoattractants for
human MM cells and are involved in MM cell migration to BM
stroma. These findings indicate a contribution of the chemokine
receptor CCR2 to the homing of MM cells to the BM
microenvironment.
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